Hypermarcas (OTCMKTS:HYPMY) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Hypermarcas (OTCMKTS:HYPMY) announced its earnings results on Wednesday. The company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.14 by $0.01, Zacks reports. The firm had revenue of $473.13 million for the quarter, compared to analysts’ expectations of $450.75 million. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%.

Hypermarcas Price Performance

Shares of HYPMY traded down $0.12 during mid-day trading on Thursday, hitting $3.96. The company’s stock had a trading volume of 63,930 shares, compared to its average volume of 46,671. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26. The firm has a 50-day moving average price of $4.63 and a 200 day moving average price of $4.41. Hypermarcas has a fifty-two week low of $3.39 and a fifty-two week high of $5.77. The stock has a market capitalization of $2.79 billion, a price-to-earnings ratio of 7.91 and a beta of 0.78.

Analyst Ratings Changes

Separately, Jefferies Financial Group upgraded Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy”.

Hypermarcas Company Profile

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.